UTHR
United Therapeutics·NASDAQ
--
--(--)
--
--(--)
UTHR fundamentals
United Therapeutics (UTHR) Revenue Breakdown: Q3 2025 Business & Regional Performance
United Therapeutics (UTHR) reported total revenue of 799.50M USD in Q3 2025, with its core business segment Tyvaso contributing 59.79%. Regionally, United States remained the largest market, accounting for 96.91% of total revenue. Explore United Therapeutics's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
United Therapeutics (UTHR) reported total revenue of 799.50M USD in Q3 2025, with its core business segment Tyvaso contributing 59.79%. Regionally, United States remained the largest market, accounting for 96.91% of total revenue. Explore United Therapeutics's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What is the revenue and EPS growth rate for United Therapeutics year over year?Did United Therapeutics beat or miss consensus estimates last quarter?What is United Therapeutics's gross profit margin?What were the key takeaways from United Therapeutics's earnings call?What factors drove the changes in United Therapeutics's revenue and profit?What is United Therapeutics's latest dividend and current dividend yield?What is the market's earnings forecast for United Therapeutics next quarter?What guidance did United Therapeutics's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
